SCCF Sachem Q4 2025 earnings vastly beat analyst expectations with shares remaining flat in regular session trading What leverage Cellyan HKPD HKPD Latest Quarter Earnings Cellyan logs zero revenue advances key drug pipeline progress STOK Stoke Therapeutics Q4 2025 EPS misses estimates by 333 pushing shares 258 lower in todays session